Percheron Therapeutics Limited has released a press release.
ATL1102 DMD Clinical Trial Application Submitted in Europe
Filed with ASX ·
6ix hasn’t read this filing yet.
Percheron Therapeutics Limited on 6ix
Earlier from Percheron Therapeutics
- New Indication for ATL1102 Limb Girdle Muscular Dystrophy R2
- Prospectus
- Bonus Option Offer
- Long COVID-19 strategic collaboration with US Experts
- Dosing commenced in MCRI collaboration animal study
Later from Percheron Therapeutics
- Voluntary Suspension
- Long Covid-19 Collaboration Outcomes Presentation
- Reinstatement to Official Quotation
- Long COVID study identifies diagnostic & therapeutic targets
- Appendix 4E and Full Year Statutory Accounts
Follow Percheron Therapeutics into a list and get an email when it puts out news.
Follow Percheron Therapeutics